Objectives: Respiratory infections with multidrug-resistant (MDR) bacteria are life-threatening in patients with cystic fibrosis (CF). Squalamine and aminosterol derivatives (ASDs) have previously demonstrated interesting antibacterial activity against bacterial reference strains. This study investigated for the first time their activity against MDR clinical isolates recovered from the sputa of CF patients.
Introduction
Bacterial pulmonary infections represent a major risk for patients with hereditary diseases such as cystic fibrosis (CF). Although the diversity of bacteria that can be recovered from sputa of patients with CF has recently expanded, 1 Pseudomonas aeruginosa and Staphylococcus aureus remain the most common pathogens in CF lung infections.
1 Antibiotic administration by inhaled aerosols may be beneficial in the management of lung infections in CF patients since antibiotics are delivered to the site of infection at high local concentrations; in addition, systemic exposure is minimized. 2 Nevertheless, multidrug resistance and biofilm formation continue to reduce the efficacy of antibiotic therapy and may render bacterial eradication unachievable. 1 Consequently, there is a great need to develop new classes of antibiotics and new therapeutic strategies that can improve therapeutic efficacy in CF patients. Squalamine, a natural aminosterol, and related synthesized aminosterol derivatives (ASDs) (Figure 1a ), demonstrated interesting in vitro antibacterial activities against reference bacterial strains. 3 The evaluation of the anti-angiogenic effect of squalamine has been investigated in a Phase I/IIA trial, demonstrating its safety after continuous 5 day infusion of 300 mg/m 2 /day. 4 However, the clinical usefulness of squalamine as an antibiotic remains uncertain. The evaluation of the antibacterial effect of these compounds against bacteria involved in clinical pathologies rather than reference strains would be more relevant. Thus, we provide herein the first study focusing on the antibacterial effect of squalamine and two ASDs synthesized in our laboratory towards a large panel of Gram-positive and Gram-negative planktonic bacteria containing multidrug-resistant (MDR) and emergent bacteria recovered from sputa of CF patients.
Materials and methods
Compounds: squalamine, ASDs 1 and 2 and antibiotic controls Squalamine was a gift from Professor M. Zasloff (Georgetown University, Washington, DC, USA). ASD 1 [7- (1,4-diaminobutane)-cholest-5-ene-3b-ol] and ASD 2 [7b-(1,4-diaminobutane)-cholestan3b-ol] were synthesized as previously reported. 5 Stock solutions were prepared in water for squalamine and in methanol for ASDs 1 and 2. Antibiotic controls were: colistin (Sanofi Aventis, Paris, France); amoxicillin (Bouchara-Recordati Laboratory, Paris, France); and vancomycin (Merck génériques, Lyon, France).
Bacterial strains
Reference strains used were Escherichia coli ATCC 25922, P. aeruginosa ATCC 27853 and S. aureus ATCC 25923. Clinical strains were isolated from the sputa of CF patients; 137 clinical strains consisting of Gram-negative (n¼ 92) and Gram-positive (n¼ 45) bacteria were tested. Phenotype identification was performed using Vitek 2 Auto systems (bioMérieux, Marcy l'É toile, France) and, when necessary, 16S rDNA or rpoB PCR 6 was employed to confirm identification. Antibiotic susceptibility testing was performed by using Vitek 2 Auto systems, Etest (AB Biodisk, 
Susceptibility testing
MICs of squalamine, ASDs 1 and 2 and antibiotic controls were determined in duplicate by the broth microdilution method. 7 MICs were defined as the lowest concentrations inhibiting bacterial growth as compared with a growth control. Controls of water or methanol were included in each plate and found to have no effect on bacterial growth. In order to examine the reproducibility of our results, evaluation of squalamine, ASDs 1 and 2 and antibiotic control activities against used reference strains was repeated 10 times.
Statistical methods
Statistical analyses were performed using the correlation or the twosample t-test options in Prism 5 for Windows (GraphPad Software). Figure 1b , part I). Furthermore, as determined from MICs, the ASDs demonstrated significantly higher activity against non-mucoid isolates (7.72+4.12 mg/L) as compared with mucoid ones (48.11+35.45 mg/L, P,0.0001). Indeed, the mucoid phenotype was significantly correlated with increased MIC values of squalamine, ASD 1 and ASD 2 (r 1 ¼0.643, r 2 ¼0.624, r 3 ¼0.638), respectively, P,0.0001; Figure 1b , part II). In order to estimate more precisely how the mucoid character of P. aeruginosa strains may affect their susceptibility to ASDs, the mucoid mode of growth of two clinical isolates was successfully suppressed. Losing the mucoid phenotype significantly increased susceptibility to the ASDs as reflected by decreased MIC values for non-mucoid strains compared with mucoid strains (Table 1) . Interestingly, ASDs were active against Gram-positive isolates with MICs ranging from 0.5 to 8 mg/L, except for Streptococcus pneumoniae isolates with MICs of 32 mg/L.
Results

Evaluation of squalamine, ASDs 1 and 2 (collectively called
ASDs for simplicity) and antibiotic control activities against reference strains was repeated and reproducible, and accurate MICs were obtained. For E. coli ATCC 25922, MICs were 2, 4, 4 and 2 mg/L for squalamine, ASD 1, ASD 2 and amoxicillin, respectively. For P. aeruginosa ATCC 27853, MICs were 8, 4, 8 and 1 mg/L for squalamine, ASD 1, ASD 2 and colistin, respectively. For S. aureus ATCC 25923, MICs were 2, 2, 4 and 0.5 mg/L for
Discussion
We report herein the first evaluation of the activity of ASDs against various bacterial clinical isolates including MDR and emergent bacteria recovered from CF patients. As depicted by MIC values (Table 1) , tested ASDs showed moderate activity against Gram-negative bacteria. However, we found that their activity was associated with resistance to colistin in this group of bacteria indicating that these compounds might probably share some mechanistic aspects with polymyxins. In agreement with our work, it was previously reported that resistance to colistin in MDR Enterobacter aerogenes isolates could also decrease the susceptibility to squalamine. 8 Resistance to colistin was reported to be due to a reduced net negative charge of the outer membrane lipopolysaccharides. 9 Recent reports indicated that this negative charge was necessary for the activity of squalamine against Gram-negative bacteria explaining the correlation with colistin activity observed in this work. 8 Furthermore, we found that the mucoid phenotype is significantly associated with higher MICs of tested ASDs and colistin. This finding had not been previously reported since the activity of ASDs against mucoid Gram-negative bacteria was evaluated for the first time in this work. 3 The mucoid phenotype is the result of an overproduction of alginates consisting of anionic exopolysaccharides (EPSs). 10 It was reported that EPSs can act as anionic shields that bind polycationic peptides such as polymyxin B leading to increased MICs of this agent for Gram-negative bacteria. 10 As tested ASDs are also cationic, the presence of EPSs might explain the elevated MICs of these compounds observed for mucoid Gram-negative isolates. On the other hand, the ASDs exhibited remarkable activity against Gram-positive isolates including methicillin-resistant S. aureus bacteria. The only exception was two isolates of S. pneumoniae. Previous reports dealing with the antibacterial activity of ASDs indicated good activity of these compounds against various Gram-positive reference strains including S. pneumoniae ATCC 6305. 3 However, it is noteworthy that the two S. pneumoniae clinical isolates tested herein were capsulated. As discussed above, the presence of EPSs in the capsule of S. pneumoniae might explain the increased MICs noticed for these bacteria as compared with other Gram-positive isolates. Hence, as reported in this study, the evaluation of ASD activity against clinical isolates provided more relevant data about the antibacterial effect of this family of compounds than previously reported using reference bacterial strains. ASDs might have the potential to be further developed as antibiotics. However, it should be noted that the MICs obtained were considerably high in some cases. Administration of antibiotics such as tobramycin and colistin in aerosols for CF patients enables the use of elevated drug doses with minimized systemic effects. 2 Thus we believe that ASDs may be developed for local administration as aerosols for the treatment of lung infections in CF patients rather than systemic administration. In conclusion, our work provides new insights into the antibacterial activities of ASDs against various Gram-negative and Gram-positive clinical isolates. Further work is warranted in order to evaluate their activity in biofilm conditions and as aerosol formulations in a lung-infected animal model.
